These results were in concordance with the results of the Peralta et al., 2012 study, which examined the association between urinary KIM-1 and NGAL levels and the development of CKD among atherosclerotic patients, concluding that elevated levels of these biomarkers were linked to an increased risk of CKD progression [27]. Here, LCN2 is linked to chronic kidney disease.